# Predicting longitudinal basal forebrain volume in the Alzheimer’s disease spectrum: the role of sex and ApoE epsilon 4 genotype

**Authors:** Alice Grazia, Fedor Levin, Frank Jessen, Michael Wagner, Oliver Peters, Josef Priller, Anja Schneider, Jens Wiltfang, Emrah Düzel, Katharina Buerger, Robert Perneczky, Christoph Laske, Annika Spottke, Alfredo Ramirez, Stefan J. Teipel

PMC · DOI: 10.3389/fnins.2026.1730947 · Frontiers in Neuroscience · 2026-02-04

## TL;DR

This study investigates how sex and the ApoE ε4 gene affect brain volume changes in Alzheimer's disease, finding that hippocampal atrophy progresses faster in ApoE ε4 homozygotes.

## Contribution

The study reveals that hippocampal atrophy, not basal forebrain atrophy, is more rapid in ApoE ε4 homozygotes, suggesting region-specific biomarker sensitivity.

## Key findings

- Hippocampal atrophy progressed significantly faster in ApoE ε4 homozygotes.
- Female participants had larger baseline basal forebrain and hippocampal volumes.
- ApoE ε4 predicted smaller baseline volumes in both regions, but only hippocampal atrophy was faster in homozygotes.

## Abstract

Imaging studies showed early atrophy of the cholinergic basal forebrain (BF) already at prodromal stages of sporadic Alzheimer’s disease (AD). Women and carriers of the ApoE epsilon 4 (ApoE ε4) allele are more likely to develop the disease; however, the underlying mechanisms are still unclear. Here we aimed at exploring the impact of sex and ApoE ε4 genotype in the AD spectrum on longitudinal measures of the basal forebrain and hippocampus, as a comparison region.

We leveraged the German multi-centered study DELCODE and analyzed 712 individuals (median age: 71.25 years, interquartile range [IQR] = 9.22) with follow-up MRI scans (median time: 2.8 years, [IQR] = 1.75). Diagnostic groups comprised cognitively normal (N = 184), subjective cognitive decline (N = 331), mild cognitive impairment (N = 128) and AD (N = 69). Regarding ApoE genotype, 5% of participants were ε4 homozygotes, while 27% were heterozygotes. Volume segmentation and linear mixed-effect models were used to calculate the effects of ApoE ε4 genotype, sex, diagnosis, age, time and their interactions in TIV-adjusted basal forebrain and hippocampal volumes.

The hippocampus, but not the basal forebrain, showed significant atrophy over time (Hipp: β = −0.014, p < 0.001; BF: β = 0.040, p = 0.044). Post-TIV correction, female participants had significantly larger baseline basal forebrain (β = 0.300, p < 0.001) and hippocampal volumes (β = 0.273, p < 0.001). ApoE ε4 predicted smaller baseline volumes in both regions. After adjusting for multiple comparisons, faster longitudinal atrophy was observed only for ApoE ε4 homozygotes in the hippocampus (β = −0.037, p < 0.001), with no corresponding effect in the basal forebrain (β = 0.000, p = 0.841).

Our findings did not show the anticipated longitudinal effects of sex and ApoE ε4 on longitudinal basal forebrain volume. Only hippocampal atrophy progressed significantly faster in ApoE ε4 homozygote carriers. This dissociation may reflect stage-dependent neurodegenerative processes, with early basal forebrain vulnerability followed by more rapid hippocampal decline, as well as methodological and sample-related constraints. If replicated, these findings suggest that hippocampal measures may be more sensitive longitudinal biomarkers in ApoE ε4 homozygotes, while sex- and ApoE ε4-related effects on the cholinergic system may be more prominent at earlier disease stages.

## Linked entities

- **Genes:** APOE (apolipoprotein E) [NCBI Gene 348]
- **Diseases:** Alzheimer’s disease (MONDO:0004975), subjective cognitive decline (MONDO:0850292)

## Full-text entities

- **Genes:** PSEN1 (presenilin 1) [NCBI Gene 5663] {aka ACNINV3, AD3, CMD1U, FAD, PS-1, PS1}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, TPSG1 (tryptase gamma 1) [NCBI Gene 25823] {aka PRSS31, TMT, trpA}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}
- **Diseases:** amyloid (MESH:C000718787), Dementia (MESH:D003704), glucose hypometabolism (MESH:D018149), deterioration in memory and executive function (MESH:D008569), AD.1 (MESH:C536594), Cognitive Decline (MESH:D003072), hippocampal volume reduction (MESH:D000092223), basal forebrain atrophy (MESH:C566067), hypertension (MESH:D006973), vascular dementia (MESH:D015140), cognitive symptoms (MESH:D019954), neuronal dysfunction (MESH:D009461), cholinergic (MESH:C535672), volume loss (MESH:D016388), Neurodegenerative Diseases (MESH:D019636), sleep deficit (MESH:D012893), AD (MESH:D000544), neurological or psychiatric disease (MESH:D001523), brain atrophy (MESH:C566985), Neuroinflammation (MESH:D000090862), atrophy (MESH:D001284)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** E280A

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12913565/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12913565/full.md

## References

60 references — full list in the complete paper: https://tomesphere.com/paper/PMC12913565/full.md

---
Source: https://tomesphere.com/paper/PMC12913565